GuidelinesOther guideline
Alimentary Tract and Metabolism
Ondansetron, Granisetron Ursodeoxycholic acid Sulfasalazine Mesalazine Pioglitazone Insulin detemir, Insulin glargine Micronutrients Glutamine Proton pump inhibitors, IV ATC Code A04AA01/ A04AA02 Medicine Serotonin-3 (5HT3) antagonists: Ondansetron, Granisetron Indication Highly or moderately emetogenic chemotherapy NEMLC Recommendation Approved Review Indicators n/a Date Ratified 20 Septe
Insulin detemir, Insulin glargine
|
ATC Code
|
A04AA01/ A04AA02
|
|
Medicine
|
Serotonin-3 (5HT3) antagonists:
Ondansetron, Granisetron
|
|
Indication
|
Highly or moderately emetogenic chemotherapy
|
|
NEMLC Recommendation
|
Approved
|
|
Review Indicators
|
n/a
|
|
Date Ratified
|
20 September 2007 (Indication updated 29 July 2021)
|
|
ATC Code
|
A05AA02
|
|
Medicine
|
Ursodeoxycholic acid
|
|
Indication
|
Primary biliary cirrhosis
|
|
NEMLC Recommendation
|
Not Approved
|
|
Review Indicators
|
The emergence of new evidence of efficacy with regard to mortality or transplantation
|
|
Date Ratified
|
13 March 2008
|
|
ATC Code
|
A07EC01
|
|
Medicine
|
Sulfasalazine
|
|
Indication
|
Ulcerative colitis
|
|
NEMLC Recommendation
|
Approved
|
|
Review Indicators
|
n/a
|
|
Date Ratified
|
16 May 2024
|
|
ATC Code
|
A07EC02
|
|
Medicine
|
Mesalazine (rectal)
|
|
Indication
|
Ulcerative colitis
|
|
NEMLC Recommendation
|
Approved
|
|
Review Indicators
|
n/a
|
|
Date Ratified
|
16 May 2024
|
|
ATC Code
|
A07EC02
|
|
Medicine
|
Mesalazine (oral)
|
|
Indication
|
Ulcerative colitis – maintenance of remission
|
|
NEMLC Recommendation
|
Approved - Special Access
Special access may be granted based on recommendation by PTC for patients with sulfonamide hypersensitivity |
|
Review Indicators
|
Price (to be evaluated as a therapeutic class with sulphasalazine)
|
|
Date Ratified
|
October 2015
|
|
ATC Code
|
A10BG03 |
|
Medicine
|
Pioglitazone |
|
Indication
|
Type 2 diabetes mellitus |
|
NEMLC Recommendation
|
Not Approved |
|
Review Indicators
|
Robust safety data |
|
Date Ratified
|
February 2012 |
|
ATC Code
|
A10AE04 |
|
Medicine
|
Long acting insulin analogues: Insulin glargine |
|
Indication
|
Diabetes mellitus |
|
NEMLC Recommendation
|
Approved - interim approval Interim approval of specific contracted item to facilitate access due to current medicine availability challenge: - Contracted item approved for use at all levels of care - Overall review of insulin analogues to continue in 2025 Also refer to approved circular: https://www.health.gov.za/wp- \content/uploads/2024/10/Analogue-insulin-EML-statuswith-Annexures_17-October-2024.pdf |
|
Review Indicators
|
Prioritised for full review for use at all levels of care |
|
Date Ratified
|
10 October 2024 Previous decision to not approve 30 June 2016 |
|
ATC Code
|
A10AB06 |
|
Medicine
|
Ultra-short-acting insulin analogues Insulin glulisine |
|
Indication
|
Diabetes mellitus |
|
NEMLC Recommendation
|
Approved - interim approval Interim approval of specific contracted item to facilitate access due to current medicine availability challenge: - Contracted item approved for use at all levels of care - Overall review of insulin analogues to continue in 2025 Also refer to approved circular: https://www.health.gov.za/wp- \content/uploads/2024/10/Analogue-insulin-EML-statuswith-Annexures_17-October-2024.pdf |
|
Review Indicators
|
Prioritised for full review for use at all levels of care |
|
Date Ratified
|
10 October 2024 Previous decision to not approve 30 June 2016 |
|
ATC Code
|
A11/A12
|
|
Medicine
|
Micronutrients
|
|
Indication
|
Addition to Parenteral Nutrition for long-term use
|
|
NEMLC Recommendation
|
Approved
- Approved for use where long-term parenteral nutrition is required/anticipated
- Short- term Total Parenteral Nutrition (TPN) should be done with off the shelf parenteral nutrition bags – no added micronutrients
|
|
Review Indicators
|
New evidence
|
|
Date Ratified
|
19 March 2020
|
|
ATC Code
|
A16AA03 |
|
Medicine
|
Glutamine |
|
Indication
|
Glutamine as a component of enteral and parenteral nutrition in critically ill patients |
|
NEMLC Recommendation
|
Not Approved |
|
Review Indicators
|
- Robust safety data - Evidence of mortality efficacy |
|
Date Ratified
|
30 June 2016 |
|
ATC Code
|
A02BC01/ A02BC05/ A02BC02
|
|
Medicine
|
Proton pump inhibitors (PPIs), IV
Omeprazole, IV Esomeprazole, IV Pantoprazole, IV |
|
Indication
|
For hospitalised patients requiring PPI therapy and who are unable to take these orally or via nasogastric tube |
|
NEMLC Recommendation
|
Approved
Only for hospitalised patients are unable to take PPIs orally or via nasogastric tube |
|
Review Indicators
|
n/a
|
|
Date Ratified
|
Class defined: 30 March 2023 (Initial recommendation: 24 June 2021)
|